Liminal BioSciences Inc.
LMNL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $3 | $5 |
| % Growth | -37.6% | -80.6% | -32.4% | – |
| Cost of Goods Sold | $0 | $0 | $2 | $3 |
| Gross Profit | $0 | $1 | $1 | $2 |
| % Margin | 100% | 100% | 38.7% | 43.7% |
| R&D Expenses | $15 | $18 | $57 | $75 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $18 | $32 | $39 | $45 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $33 | $50 | $95 | $120 |
| Operating Income | -$33 | -$50 | -$94 | -$211 |
| % Margin | -8,223.2% | -7,707.2% | -2,842.1% | -4,295.1% |
| Other Income/Exp. Net | -$1 | $0 | -$28 | -$0 |
| Pre-Tax Income | -$29 | -$45 | -$122 | -$234 |
| Tax Expense | -$1 | $0 | -$0 | -$0 |
| Net Income | -$29 | -$45 | -$122 | -$234 |
| % Margin | -7,211% | -7,008.2% | -3,682.2% | -4,776.2% |
| EPS | -341.8 | -532.66 | -1,443.7 | -2,768.61 |
| % Growth | 35.8% | 63.1% | 47.9% | – |
| EPS Diluted | -9.32 | -14.94 | -49.97 | -145.82 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $6 | $9 | $14 |
| Depreciation & Amortization | $1 | $4 | $8 | $10 |
| EBITDA | -$32 | -$45 | -$105 | -$201 |
| % Margin | -7,943.9% | -7,031.6% | -3,170.5% | -4,093.1% |